

Original article

Association of severe preeclampsia and vascular damage assessed by noninvasive markers of arterial stiffness

Lara Belmar Vega^{a,*}, José Luis Pérez Canga^a, Milagros Heras Vicario^a, Emilio Rodrigo Calabria^a, Juan Carlos Ruiz San Millán^a, Laura Díaz López^b, Luis Martín Penagos^a, Gema Fernández Fresnedo^a

^a Servicio de Nefrología, Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain

^b Servicio de Obstetricia y Ginecología, Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain

ARTICLE INFO

Article history:

Received 18 April 2022

Accepted 23 July 2022

Available online 9 January 2024

Keywords:

Preeclampsia

Arterial stiffness

Carotid-femoral pulse wave velocity

Central augmentation index

Central augmentation pressure

ABSTRACT

Background: Preeclampsia (PE) is a hypertensive disorder of pregnancy associated with high maternal and fetal morbidity and mortality and increased future risk of cardiovascular complications.

Objective: To analyze whether women who have had PE with severe features in their pregnancy have higher arterial stiffness (AS) parameters than those whose PE course was without signs of severity.

Methods: Sixty-five women who developed PE during their gestation were evaluated, divided into two groups: PE group without severe features or non-severe PE ($n = 30$) and PE group with severe features or severe PE ($n = 35$). Carotid-femoral pulse wave velocity (cfPWV), central augmentation index corrected to a heart rate of 75 beats per minute (AIxc75) and central augmentation pressure (cAP) were determined one month and six months postpartum. Comparison of proportions was carried out using the chi-square test, comparison of means between groups using the Student's t-test or the Mann-Whitney test, and comparison of means of the same group at different evolutionary moments, using the t-test or the Wilcoxon test. Correlation, with and between hemodynamic parameters, was carried out with Spearman's correlation coefficient and the association between demographic variables, personal history and hemodynamic parameters, and altered arterial stiffness parameters was carried out using linear and logistic regression models.

Results: Women with severe PE presented, both at 1 and 6 months postpartum, higher values of blood pressure, both central and peripheral, as well as AR and pulse amplification parameters, than those women whose PE was not severe. Central augmentation index (cAIx) values at 1 month and 6 months postpartum were higher, although not significantly, in the severe PE group compared to the non-severe PE group (24.0 (16.5–34.3) vs. 19.0% (14–29) and 24.0 (14.0–30.0) vs. 20.0% (12.3–26.8), respectively). Carotid-femoral pulse wave velocity (cfPWV) was significantly higher at both 1 and 6 months postpartum in the severe PE group compared to the non-severe PE group (10.2 (8.8–10.7) vs. 8.8 m/s (8.3–9.6) and 10.0 (8.8–10.6)

DOI of original article:

<https://doi.org/10.1016/j.nefro.2022.07.007>.

* Corresponding author.

E-mail address: belmarvega@outlook.es (L. Belmar Vega).

2013-2514/© 2022 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

vs. 8.8 m/s (8.3–9.3), respectively). Central systolic pressure and central pulse pressure amplification were also higher, although not significantly, in the severe PE group in comparison with the non-severe PE group.

Conclusions: Women who have had severe PE have more pronounced arterial stiffness parameters than those in whom PE was not particularly severe. The determination of cAIx and cfPWV, as a strategy for the assessment of cardiovascular risk, should be evaluated among women who have had PE.

© 2022 Sociedad Española de Nefrología. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Asociación de preeclampsia grave y daño vascular valorado por marcadores no invasivos de rigidez arterial

R E S U M E N

Palabras clave:

Preeclampsia
Rigidez arterial
Velocidad de onda de pulso carótida-femoral
Índice de aumento central
Presión de aumento central

Antecedentes: La preeclampsia (PE) es un trastorno hipertensivo del embarazo asociado a una elevada morbilidad materna y fetal, y un mayor riesgo futuro de complicaciones cardiovasculares.

Objetivo: Analizar si las mujeres que han tenido PE grave en su embarazo presentan parámetros de rigidez arterial (RA) superiores a las de aquellas cuya PE cursó sin signos de gravedad. **Métodos:** Se evaluaron 65 mujeres que habían desarrollado PE durante su gestación, divididas en 2 grupos: grupo de PE sin criterios de gravedad o PE no grave (n=30) y grupo de PE con criterios de gravedad o PE grave (n=35). Se determinó la velocidad de onda de pulso carótida-femoral (VOPcf), el índice de aumento central normalizado a 75 latidos por minuto (IAC75) y presión de aumento central (PAC) al mes y a los 6 meses posparto. La comparación de proporciones se llevó a cabo mediante la prueba de Chi-cuadrado, la comparación de medias entre grupos se utilizaron la prueba t de Student o la prueba de Mann-Whitney, y la comparación de medias de un mismo grupo en momentos evolutivos diferentes, la prueba t para o el test de Wilcoxon. La correlación, con y entre parámetros hemodinámicos, se llevó a cabo con el coeficiente de correlación de Spearman y la asociación entre variables demográficas, antecedentes personales y parámetros hemodinámicos, y valores alterados de RA se llevó a cabo mediante modelos de regresión lineal y logística.

Resultados: Las mujeres con PE grave presentaban, al mes y a los 6 meses posparto, valores de presión arterial, tanto central como periférica, así como parámetros de RA y amplificación de pulso, superiores a aquellas mujeres cuya PE no revistió gravedad. Los valores del índice de aumento central (IAC) al mes y a los 6 meses posparto fueron superiores, aunque no de forma significativa, en el grupo de PE grave respecto al grupo de PE no grave (24,0 [16,5–34,3] vs. 19,0% [14–29] y 24,0 [14,0–30,0] vs. 20,0% [12,3–26,8], respectivamente). La velocidad onda de pulso carótida-femoral (VOPcf) fue superior de forma significativa, tanto al mes como a los 6 meses posparto en el grupo de PE grave respecto al grupo de PE no grave (10,2 [8,8–10,7] vs. 8,8 m/s [8,3–9,6] y 10,0 [8,8–10,6] vs. 8,8 m/s [8,3–9,3], respectivamente). La amplificación de la presión sistólica central y de la presión de pulso central fueron también superiores, aunque no de forma significativa, en el grupo de PE grave respecto al de PE no grave.

Conclusión: Las mujeres que han tenido PE grave presentan parámetros de RA más acusados que los de aquellas en las que la PE no revistió especial gravedad. Debiera evaluarse la conveniencia de incluir de forma rutinaria entre las mujeres que han tenido PE la determinación del IAC y especialmente la VOPcf, como estrategia de evaluación del riesgo cardiovascular.

© 2022 Sociedad Española de Nefrología. Publicado por Elsevier España, S.L.U. Este es un artículo Open Access bajo la licencia CC BY-NC-ND (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

Preeclampsia (PE) is a hypertensive disorder of pregnancy associated with high maternal and fetal morbidity and mortality. It has a multifactorial etiology, placental factors associated

with decreased placental perfusion, maternal clinical risk factors such as hypertension (HTN), age, obesity, diabetes mellitus (DM) or thrombophilia.^{1,2} The link between relative placental hypoxia and the clinical syndrome includes a cascade of secondary mechanisms including an imbalance between pro-angiogenic and anti-angiogenic factors, mater-

nal oxidative stress and endothelial and immune dysfunction, which would be responsible for generalized endothelial dysfunction leading to arterial stiffness (AS), and whose development is associated with cardiovascular (CV) damage.³

In recent years, new non-invasive techniques have been developed to assess endothelial function in peripheral vessels, including pulse wave velocity (PWV) as a marker of AS and clinical assessment of endothelial function.⁴

AS is an independent predictor of morbidity and mortality, and its increase, mainly associated with age, gender, and blood pressure (BP), is associated with the development of cardiovascular disease (CVD) and all-cause mortality, regardless of the presence of other cardiovascular risk factors (CVR).⁵ Therefore, early detection of BP can play an important role in the prevention of this type of disease.

The BP is conventionally measured over the brachial artery, and constitutes the reference standard for the diagnosis and management of hypertension. Its parameters are powerful predictors of CV structural damage, morbidity and mortality. However, the phenomena of amplification and reflection of the pulse wave that occur along the arterial tree, determine that the central BP (cAP), more representative of the load exerted on major organs such as the heart, brain and kidneys, differs substantially from the peripheral arterial pressure (pAP)⁶ and, although current European guidelines for the management of HTN question the prognostic value of cAP measurement in clinical practice,⁷ several studies point to the relevance and superiority of cAP over pAP in risk assessment, prediction of target organ damage, adverse CV events, and mortality.^{8–11} On the other hand, it has been suggested that the assessment of cAP can improve therapeutic decisions since certain antihypertensive drugs can have substantially different effects on cAP despite having similar effects on pAP.⁶

Several hemodynamic parameters are associated with AS. Among them, the most studied are the augmentation index (AI) and PWV. The value of AI depends on AS and it is influenced by wave reflections along the arterial tree, and although it is technically easier to measure than PWV and is related to CVR factors, coronary artery disease and death due to CVD,¹² its dependence on age¹³ and the possibility of being affected by certain antihypertensive treatments,⁶ means that it is considered an indirect marker of AS, not interchangeable with PWV.¹⁴ The measurement of PWV is a noninvasive, innocuous, short-duration procedure and simple to perform in health care practice. Given its reliability and the large amount of evidence demonstrating its association with CVD, regardless of existing risk factors, carotid-femoral PWV (cfPWV) is the gold standard for the quantification of AS, and it is considered one of the markers of organ damage with the highest predictive CV value, greater reproducibility and acceptable cost-effectiveness ratio.^{7,15}

Normal values of pAP are well defined⁷ and, although there are studies that propose normal values and reference ranges for various parameters of cAP, AS and pulse wave amplification,^{13,16–20} the heterogeneity of the populations analyzed and the absence of a standardized methodology for their evaluation generally make it difficult to implement their use in clinical practice.

Our objective is to analyze whether women who have had severe PE during pregnancy have higher AS parameters than those whose PE had no signs of severity.

Material and methods

Study population

This is a prospective study carried out on 65 consecutive women with development of PE during pregnancy that were referred from the Gynecology and Obstetrics Department Gravídica Pathology Unit to the Nephrology Department of the Marqués de Valdecilla University Hospital between 01/01/2021 and 30/06/2021.

According to the severity of PE, the cohort was divided into 2 groups, PE group without severity criteria or “non-severe PE” (n=30) and PE group with presence of with criteria of severity or “severe PE” (n=35). The diagnosis and classification of PE according to severity was established according to The American College of Obstetricians and Gynecologists (ACOG) criteria.²¹ Early-onset PE was defined as a diagnosis of PE before 34 weeks of gestation.²² Demographic parameters, CVR factors, obstetric history and gestational data were collected by personal interview with the patient that was cross-checked with her medical history. The study was conducted following the rules of the Declaration of Helsinki and approved by the Clinical Research Ethics Committee of our institution (reference number: 2018.170). All participants gave their informed consent.

Analytical determinations

Serum creatinine and proteinuria values at the time of PE diagnosis were collected from the patient's clinical history.

Hemodynamic determinations

Peripheral and central hemodynamic parameters were determined by the same trained observer, noninvasively, using an automated SphygmoCor[®] XCEL device (AtCor Medical Pty. Ltd., Sydney Australia). Peripheral systolic blood pressure (SBPp) and peripheral diastolic blood pressure (DBPp), were recorded using an appropriately sized brachial cuff, placed on the dominant arm, with the patient seated and with the back and arm resting on a rigid surface after a rest period of at least 5 min. Three measurements were made, the first one was discarded and the last 2 averaged. Peripheral pulse pressure (PPp) was defined as (pPP = pSBP – pDBP). For the determination of peripheral mean arterial pressure (pMBP), the following approximation was applied²³: pMBP = pDBP + 0.4 × pPP.

The SphygmoCor[®] XCEL system derives the central aortic pressure waveform from the pulses recorded by the cuff placed on the brachial artery, using a generalized transfer function integrated into the device software (version 1.3). The aortic waveform analysis provides key parameters including central systolic arterial pressure (cSBP), central diastolic arterial pressure (cDBP) and central pulse pressure (cPP), calculated as cPP = cSBP – cDBP, central mean arterial pres-

sure (c MBP), and AS indices such as central augmentation pressure (AG), defined as the difference between the second and first systolic peak, and central augmentation index (AIx), defined as cAP expressed as a percentage of PPc, as well as its value standardized to a standard heart rate (HR) of 75 beats per minute (IAC75). Three measurements were made, the first one being discarded and the last 2 valid determinations of the central hemodynamic parameters were averaged. Systolic arterial pressure amplification (aSBP), was expressed as the difference of pSBP and cSBP ($aSBP = pSBP - cSBP$) and pulse pressure amplification (aPP), was quantified in 3 ways: (a) as the difference between pPP and cPP ($aPP = pPP - cPP$), (b) as percentage increase between pPP and cPP ($aPP = [pPP - cPP] / cPP \times 100$) and (c) by the ratio of pPP and cPP ($aPP = pPP / cPP$).²⁴

Determination of PWVcf was performed from carotid and femoral arterial pulses measured noninvasively. Carotid pulse waves were measured by applanation tonometry and femoral pulse waves were obtained simultaneously using a partially inflated cuff over the femoral artery in the leg midway between the hip and knee. The PWVcf was determined by calculating the ratio of the corrected distance between pulse measurement sites to the time delay between carotid and femoral pulse waves. The subtraction method was used to calculate the distance, whereby the path length was calculated by subtracting from the distance between the suprasternal notch and the top of the thigh cuff, the distance between the suprasternal notch and the carotid site and the distance from the femoral artery at the inguinal ligament to the proximal edge of the thigh cuff. Two valid measurements of PWVcf were averaged.

Abnormal PWVcf values were considered to be those that exceeded the median value, for the corresponding age group, assigned to the reference population by "The Reference Values for Arterial Stiffness Collaboration".¹⁶ Abnormal values of SBPc and aPSc were considered to be those that exceeded the median value for the corresponding age group assigned to the reference population in the study by Herbert et al.¹⁷

Statistical analysis

Continuous variables are presented as mean and standard deviation (SD) or median and interquartile range (IQR). Comparison of proportions was performed using the Chi-square test. Comparison of means between different groups was performed using Student's t-test for independent samples or the Mann-Whitney test, and the t-test for related samples or the Wilcoxon test in the case of comparison of means of the same group at different evolutionary moments. Correlation with and between hemodynamic parameters was carried out using Spearman's correlation coefficient. Linear and logistic regression models were used to evaluate the association between known CVR factors and the main AS parameters. In all hypothesis contrasts, the null hypothesis was rejected with a type I error or α error <0.05. Analyses were performed with SPSS software[®] version 22 (SPSS, Chicago, IL, USA).

Results

Baseline data

We evaluated 30 women with non-severe PE and 35 women with severe PE, whose baseline data are shown in Table 1. There were no significant differences in age, CV risk factors or obstetric history between the two groups. As compared with PE without severity criteria, Women with severe PE had their delivery earlier (35.7 ± 4.1 weeks in severe PE vs., 38.1 ± 2.3 weeks in non-severe PE; $p = 0.006$) and used cesarean section more often as a form of gestational termination (51.4% in severe PE vs. 26.7% in PE without severity criteria; $p = 0.042$). In relation to the time of the initiation of PE, early PE was observed in 22.9% of severe PE cases and in 13.3% of non-severe PE cases. Twenty percent of severe PE cases did not have proteinuria. Newborns from mothers with severe PE had a lower birth weight than those from mothers with non-severe PE, although the differences did not reach statistical significance.

In the analysis of renal function at the time of PE diagnosis, the non-severe PE group had significantly higher proteinuria values than the severe PE group ($851.5 [566.0 - 1520.3]$ vs. $561.0 \text{ mg}/24 [359.3 - 799.0]$; $p = 0.018$). Values of serum creatinine values were not significantly different in the two groups.

Vascular parameters

Table 2 shows the vascular parameters obtained with the SphygmoCor[®] XCEL system at 1 and 6 months after delivery. The analysis of pAP and cAP did not show substantial differences within each group between the two evolutionary moments. However, the comparison between the two groups showed that women with severe PE compared to non-severe PE, had statistically significant higher values of SBP (up to 11 mmHg at the peripheral level and 12 mmHg at the central level), DBP (8 mmHg at the peripheral level and 10 mmHg at the central level) and MBP (9 mmHg at the peripheral level and up to 12 mmHg at the central level).

Among the main central AS parameters (cAP, and cAI), no significant differences were observed in intragroup comparisons. However, the comparison between both groups reflected that women with severe PE had higher values of cAP (up to 3 mmHg) and cAI (5% and 9% in IAC75), than women with non-severe PE, although the differences did not reach statistical significance. Regarding pulse wave amplification, in women with non-severe PE, no differences were observed, between the two evolutionary periods, in both acSP and acPP, whereas in severe PE there were significant increases, between month 1 and month 6 postpartum, of the order of 2 mmHg in acSBP ($10.5 [8.0 - 12.3]$ vs. $13.0 \text{ mmHg} [10.8 - 15.0]$; $p < 0.001$ (approximately 1.7%) and of 3 mmHg in acPP $11.0 (7.0 - 13.0)$ vs. $14.0 \text{ mmHg} (10.8 - 16.3)$; $p = 0.001$ (approximately 8%). The comparison between the two groups showed that, neither acSBP nor acPP were significant different at any of the time points analyzed.

Regarding cfPWV, the intra-group comparison did not show significant variations between the two evolutionary moments. However, the comparison cfPWV between the two groups did reflect significant differences, both at one month postpar-

Table 1 – General description of the population.

	Non-severe PE (n = 30)	Severe PE (n = 35)	p Value
Age	33.6 ± 6.5	35.0 ± 6.1	0.393
Age range. n (%)			
<30 years	6 (20.0)	6 (17.1)	0.459
From 30 to 39 years old	20 (66.7)	22 (62.9)	0.705
>39 years	4 (13.3)	7 (20.0)	0.248
Cardiovascular risk factors. n (%)			
Pre-pregnancy hypertension	–	–	–
DM	2 (6.7)	2 (5.7)	0.873
Dislipemia	–	–	–
Smoking	1 (3.3)	–	–
Persistence HTA 6 month postpartum.	–	2 (5.7)	–
Obstetric history. n (%)			
Number of previous pregnancies			0.313
None	20 (66.7)	18 (51.4)	
One or more	10 (33.3)	17 (48.6)	
Pre-abortions	3 (10.0)	7 (20.0)	0.319
PE previous	5 (16.7)	4 (11.4)	0.542
Current gestational data			
Multiple pregnancy. n (%)	4 (13.3)	2 (5.7)	0.403
Assisted reproductive techniques. n (%)	8 (26.7)	4 (11.4)	0.208
Cesarean delivery. n (%)	8 (26.7)	18 (51.4)	0.042
Weeks of labor. mean ± DE	38.1 ± 2.3	35.7 ± 4.1	0.006
HELLP. n (%)	–	6 (17.1%)	–
Eclampsia. n (%)	–	–	–
PE classification according to time of onset. n (%)	0.324		
Early	4 (13.3)	8 (22.9)	
Late	26 (86.7)	27 (77.1)	
Maternal complications			
Membrane rupture prematurely n (%)	1 (3.3)	1 (2.9)	0.912
Bleeding n (%)	1 (3.3)	3 (8.6)	0.381
Epigastralgia n (%)	–	9 (25.7)	–
Headache n (%)	–	15 (42.9)	–
Pulmonary edema n (%)	–	–	–
Visual alterations n (%)	–	2 (5.7)	–
Analytical alterations n (%)			
Proteinuria n (%)	30 (100)	28 (80.0)	0.010
Proteinuria (mg/24 h). Me (RIC)	851.5 (566.0–1.520.3)	561.0 (359.3–799.0)	0.018
Kidney function impairment n (%)	–	2 (5.7)	–
Creatinine (mg/dl). Me (RIC)	0.69 (0.61–0.87)	0.64 (0.56–0.78)	0.426 h
Thrombocytopenia n (%)	–	6 (17.1)	–
Alteration liver function tests n (%)	–	6 (17.1)	–
PAS ≥ 160 and/or PAD ≥ 110 mmHg. n (%).	–	25 (71.4)	–
BP at diagnosis (mmHg). mean ± DE.			
SBP	150.9 ± 7.5	165.9 ± 20.4	<0.001
DBP	91.3 ± 7.5	98.1 ± 12.4	0.010
Newborn data			
Birth weight (mg) mean ± DE	3.076.3 ± 446.3	3.015.1 ± 326.2	0.744
IUGR n (%)	1 (3.3)	3 (8.6)	0.381

BP, blood pressure; DBP, diastolic blood pressure; SBP, systolic blood pressure; IUGR, intrauterine growth retardation; PE, preeclampsia.

tum, 8.8 (8.3–9.6) in the non-severe PE group vs. 10.2 m/s (8.8–10.7) in the severe PE group, $p=0.003$, and at 6 months postpartum 8.8 (8.3–9.3) m/s in the non-severe PE group vs. 10.0 (8.8–10.6) m/s in the severe PE group; $p=0.006$.

Fig. 1 shows the comparisons between the non-severe PE and severe PE groups for the main parameters analyzed by age range (<30, and ≥40 years).

Modification of arterial stiffness parameters

Change of cfpWV

One month postpartum, 90 and 94.3% of women of the non-severe PE and severe PE groups, respectively, had altered cfpWV values, and in a total of 19 women (3 in the non-severe PE group and 15 in the severe PE group), cfpWV was greater

Table 2 – Vascular parameters as a function of preeclampsia severity.

	PE not severe			Severe PE			PE non-severe vs. severe	
	One month	6 months	p Value	One month	6 months	p Value	One month	6 Months
<i>Peripheral parameters</i>								
pSBP (mmHg), mean (IR)	120.0 (110–127.3)	120.0 (115.8–127.8)	0,316	129,0 (116,0–136,0)	131,0 (119,0–147,0)	0,065	0,012	0,003
pDBP (mmHg), me (IR)	73.0 (68.0–80.5)	73.0 (67.0–77.3)	0.304	81.0 (75.0–86.0)	81.0 (74.0–89.0)	0.893	0.002	0.001
pPP (mmHg). Mean (IR)	45.0 (41.5–50.0)	47.5 (44.0–51.3)	0.017	46.0 (41.0–51.0)	51.0 (45.0–56.0)	0.009	0.425	0.104
pMBP (mmHg) ^a . Mean (IR)	91.2 (85.3–98.7)	92.5 (87.3–96.8)	0.991	100.0 (91.4–104.2)	99.4 (91.6–111.6)	0.326	0.003	0.000
HR (lpm). Mean (IR)	70.0 (65.0–75.0)	68.0 (60.8–72.8)	0.416	70.5 (64.0–76.3)	70.0 (64.0–77.0)	0.555	0.668	0.179
<i>Central parameters</i>								
cSBP (mmHg), mean (IR)	107.0 (98.5–114.0)	108 (102.5–116.3)	0.305	119.0 (109.5–125.8)	119.0 (108.0–135.5)	0.586	0.000	0.004
cDBP (mmHg). Mean (IR)	72.0 (68.0–79.0)	73.5 (67.8–77.5)	0.000	82.0 (76.0–88.0)	82.5 (74.0–92.5)	0.000	0.001	0.001
cPP (mmHg). Mean (IR)	32.0 (29.0–36.0)	35.0 (32.0–39.0)	0.118	35.5 (29.8–43.8)	37.0 (32.5–43.3)	0.587	0.104	0.435
MBP (mmHg). Mean (IR)	87.0 (81.5–94.5)	87.5 (81.0–92.0)	0.891	99.0 (89.5–102.3)	96.0 (89.0–108.0)	0.450	0.001	0.000
cAP (mmHg). Mean (IR)	6.0 (4.3–9.8)	7.0 (3.8–9.0)	0.310	9.0 (4.8–13.0)	9.0 (6.0–11.0)	0.776	0.109	0.126
cAI. %	19.0 (14–29)	20.0 (12.3–26.8)	0.135	24.0 (16.5–34.3)	24.0 (14.0–30.0)	0.379	0.178	0.228
cAI75. %	16.0 (11.5–27.5)	14.0 (7.0–23.0)	0.045	22.0 (16.8–30.8)	23.0 (11.0–29.0)	0.629	0.095	0.027
<i>Pulse amplification</i>								
cSPa (mmHg)	12.0 (9.0–14.0)	13.0 (11.0–14.3)	0.162	10.5 (8.0–12.3)	13.0 (10.8–15.0)	0.000	0.153	0.584
cSPa (%)	11.3 (8.4–13.7)	11.5 (8.8–14.3)	0.469	9.5 (6.4–10.9)	11.2 (9.2–13.4)	0.001	0.010	0.527
cPPa (mmHg)	11.0 (9.5–14.0)	13.0 (11.0–15.0)	0.155	11.0 (7.0–13.0)	14.0 (10.8–16.3)	0.001	0.364	0.351
cPPa (%)	37.9 (29.0–41.4)	37.4 (31.1–44.3)	0.381	28.9 (16.7–38.1)	37.0 (29.1–45.2)	0.013	0.057	0.824
Ratio pPP/cPP	1.4 (1.3–1.4)	1.4 (1.3–1.4)	0.381	1.3 (1.2–1.4)	1.4 (1.3–1.5)	0.013	0.057	0.824
<i>Other parameters</i>								
cfPWV (m/s)	8.8 (8.3–9.6)	8.8 (8.3–9.3)	0.738	10.2 (8.8–10.7)	10 (8.8–10.6)	0.575	0.003	0.006

pSBP: peripheral systolic arterial pressure; pDBP: peripheral diastolic arterial pressure; pPP: peripheral pulse pressure; pMBP^a: peripheral mean arterial pressure; HR: heart rate; cSBP: central systolic arterial pressure; cDBP: central diastolic arterial pressure; cPP: central pulse pressure; cMBP: central mean arterial pressure; cAP : central augmentation pressure; cAI: central augmentation index; cAI75: central augmentation index normalized to 75 lpm; cSPa: central systolic pressure amplification; cPPa: central pulse pressure amplification; cfPWV: carotid-femoral pulse wave velocity.

^a Calculated as: pMBP = pDBP + 0.4 × pPP.




Fig. 1 – Arterial stiffness parameters at 1 month and 6 months as a function of preeclampsia severity and age range. IAcf75: central augmentation index normalized to 75 lpm; cAP: central augmentation pressure; PE: preeclampsia; cfPWV: carotid-femoral pulse-wave velocity.

than 10 m/s. At 6 months postpartum, 100% of women in both groups had altered cFPWV values, and 1 woman in the non-severe PE group and 10 in the severe PE group had a cFPWV ≥ 10 m/s.

Changes cSBP

One month postpartum, 34.5% of the women from non-severe PE group and 70.6% in the severe PE group had altered SBP values. Six months after delivery, the alteration was observed in 50 and 73.5% of women, respectively.

Alteration of pulse amplification

In the non-severe PE group, 79.3% and 86.7% of the women had median acSBP values higher than those established for their reference age group at 1 and 6 months postpartum, respectively. In the severe PE group, the alteration was observed in 76.5% and 91.2%, respectively.

Correlation and association

Correlation analysis of the main AS parameters reflected that, in the non-severe PE group, cFPWV correlated 1 month postpartum with pSBP ($\rho=0.462$) and at 6 months postpartum it correlated with age and with pSBP ($\rho=0.416$ and 0.603), respectively. In the severe PE group, one month postpartum it correlated with pSBP ($\rho=0.308$) and at 6 months postpartum with age and cAI ($\rho=0.607$ and 0.448), respectively.

In addition, in the non-severe PE group, 1 month postpartum cAI correlated with cFPW, cPP and with cAP ($\rho=0.443$, 0.591 and 0.973 respectively), and at 6 months postpartum with age, pSBP, cFPWV and with cAP ($\rho=0.423$, 0.464 , 0.448 and 0.965 , respectively). In the severe PE group, one month postpartum cAI correlated with age, pSBP, cPP and cAP ($\rho=0.448$, 0.473 , 0.668 and 0.955 respectively), and at 6 months postpartum with age, cFPWV, cPP and cAP ($\rho=0.351$, 0.550 , 0.578 and 0.928 respectively).

In linear regression models, we found no association between AS parameters with height, body mass index (BMI), or the prevalence of CV risk factors such as dyslipidemia, smoking, obesity, and DM. In the logistic regression models, we also found no association between these factors and altered values of the main AS parameters.

Discussion

The main finding of the present study was that women with severe PE have higher values, both at 1 and 6 months postpartum, of cAP and pAP, as well as AS and pulse amplification parameters, than women with non-severe PE.

In preeclamptic women, even after normalization of BP after delivery, it has been observed persistence, even up to several years, of altered AS indices,²⁵⁻²⁸ which may provide a potential explanation for the increased CV risk in these women.²⁹⁻³² However, studies assessing endothelial dysfunction and AS several years after preeclamptic pregnancy have been inconclusive.³³⁻³⁵ To our knowledge, this is the first study to consistently analyze AS and pulse wave amplification as a function of PE severity. Previous studies such as the published

by Khalil et al.³¹ observed that both cAP and cAI75, were significantly higher in severe PE than in non-severe PE ($p < 0.001$). However, pulse wave analysis to assess AS was performed 24/48 h prior to initiation of antihypertensive therapy, so they were unable to ascertain whether AS returned to normal after delivery and, if so, how long did it take. In another study, Avni et al.,³⁶ found that women who developed severe PE had higher AS parameters (cAP, cAI and cAI75) than those with non-severe PE. However, the severe PE group only included 5 women, and the determination of central vascular and AS parameters were obtained throughout the pregnancy without establishing temporal uniformity in the time of their determination. In our study, we have analyzed the evolution of AS parameters uniformly at 1 and 6 month after delivery, and it was observed that women with severe PE have more marked sustained AS parameters and pulse wave amplification than those with non-severe PE.

A close association between age and BP with AS has been found. However, the association with other CV risk factors, other than BP, such as dyslipidemia, smoking, obesity, sex, HR, and DM is inconsistent.³⁷⁻⁴¹ In absolute terms, the cAP represents the increase in aortic pressure caused by the reflection of the pulse wave through the arterial tree, and a linear increase in this parameter with age has been reported. Likewise, there is a close association between age and cAI, more marked in young individuals (younger than 50 years), and cFPWV, more sensitive in those older than 50 years, which, indicates that these 2 parameters are not interchangeable when determining AS, furthermore it suggests that cAI could be a more sensitive marker of arterial aging in younger individuals and PWV more sensitive in those older than 50 years.¹³ In our study, we only observed a consistent significant correlation in both evolutionary periods between age and cAI in the severe PE group, but not with cAP or cFPWV, a circumstance that we justify by the homogeneity of the population analyzed and the low variability in the age of the patients. As for the other CV risk factors, in our study we did not observe significant differences between the two groups of women in height, BMI, or prevalence of factors such as dyslipidemia, smoking, obesity, sex, HR and DM, nor did we find a linear correlation or association between these variables and the main AS parameters (cAP, cAI and cFPWV). Similarly, studies such as that of Wilkinson et al.,⁴² point to an inverse linear relationship between heart rate and cAI and a positive correlation with the pPP/cPP ratio, however these correlations were not observed in our study. Also, higher rates AS have been reported in early-onset PE patients than in late-onset.^{31,43} However, we, as in the systematic review by Kirolos et al.,²⁸ did not find significant differences depending on the time of onset of PE.

Pulse amplification is determined by reflection phenomena and shows great variability between different subjects and even within the same subject in the presence of certain pathophysiological changes, and with the administration of drugs that affect HR.^{44,45} A study by McEniery et al.⁴⁶ found that, in addition to age, HR, sex and height, all CV risk factors and the presence of CV disease were independently associated with the pPP/cPP ratio and the difference pSP-cSP. In our work we found no association between these pulse amplification parameters with age, height, HR, or other CV risk factors,

probably because while the aforementioned study analyzed a population with age range from ≤ 20 years to ≥ 80 years, most of them without CV risk factors, or at most with only one risk factor; by contrast the women in our study had low age variability and a low prevalence of additional CV risk factors. The specific causes of these differences in AS according to the severity of PE are not clear to us, although it is very likely that its etiology, as in PE, is multifactorial. It is possible that immunological factors play an important role in the greater stiffness observed in these patients diagnosed with severe PE, as we have observed in a previous study carried out by our team, in which we found that AS, assessed three months after delivery by analysis of cfPWV, was strongly related to the presence of IgM-antiphosphatidylserine/prothrombin antibodies, and was more intense among women with severe PE than in women whose PE was not severe.⁴⁷

Although several studies have shown the superiority of cAP over pAP in the prediction of target organ damage and CV risks,^{6,11,48} in clinical practice, HTN and CV risk are diagnosed and stratified almost exclusively on the basis of brachial BP. In fact, patients who are ascribed a certain degree of CV risk, based on a diagnosis of HTN, according to brachial BP values, could have a different CV risk if cAP values, AS parameters and pulse wave amplification were taken into consideration.¹¹ In our study, one month postpartum, 19 women (3 in the non-severe PE and 16 in the severe PE group), had a cfPWV greater than 10 m/s and 6 months postpartum, 11 women (only one in the non-severe PE group), exceeded this threshold, which according to current criteria⁷ is considered a conservative estimate of significant alterations in aortic function in middle-aged patients.

The AS promotes internal remodeling of small arteries, which increases resistance, blood pressure and, in turn, central artery stiffness, thus creating an insidious feedback loop. On the other hand, several studies find that AS is not only a powerful predictor of CV risk, but also a marker associated with the development of chronic kidney disease. AS worsens as renal function declines, is associated with proteinuria, bone and mineral disorders, and predicts death and progression of CKD to end-stage CKD.⁴⁹ Therefore, it is possible that new long-term therapeutic strategies should be considered for women who have had PE during pregnancy, especially if the pregnancy was severe, focused on the prevention or reduction of AS, combining non-pharmacological measures such as loss of body weight, reduction of salt intake and physical exercise, and if necessary, with antihypertensive pharmacological treatments and lipid-lowering and antidiabetic drugs.

The main strength of our study lies in its prospective nature and, to our knowledge, in being the first to analyze, in a consistent manner, at 1 and 6 months postpartum, AS and pulse wave amplification as a function of PE severity. The main weaknesses are the failure to extend the analysis of AS indices beyond 6 months postpartum, and the lack of information on other parameters associated with endothelial dysfunction, such as the overexpression of antiangiogenic factors like soluble factor tyrosine kinase 1fms-like (sFlt1) and soluble endoglin (sEng), or the low amount of proangiogenic factors such as placental growth factor (PlGF) and vascular endothelial growth factor (VEGF), in order to check whether the AS

observed, especially in severe PE, is maintained or attenuates over time.

In conclusion, women who have had severe PE during pregnancy have more pronounced AS parameters than those in whom PE did not show signs of severity, which indicates a higher CV risk in these patients. Thus, we consider that women who have had PE during pregnancy, should be evaluated whether measurements of cAI and especially cfPWV, that are feasible, noninvasive and replicable methods, should be routinely included in the strategies of CV risk assessment of these women.

Financing

This research has not received specific support from public sector agencies, commercial sector or non-profit entities.

Conflict of interest

The authors declare that they have no conflicts of interest.

REFERENCES

- LaMarca BD, Gilbert J, Granger JP. Recent progress toward the understanding of the pathophysiology of hypertension during preeclampsia. *Hypertension*. 2008;51:982–8, <http://dx.doi.org/10.1161/HYPERTENSIONAHA.107.108837>.
- Roberts JM, Hubel CA. The two stage model of preeclampsia: variations on the theme. *Placenta*. 2009;30 Suppl A:S32–7, <http://dx.doi.org/10.1016/j.placenta.2008.11.009>.
- Féltóu M, Vanhoutte PM. Endothelial dysfunction: a multifaceted disorder (The Wiggers Award Lecture). *Am J Physiol Heart Circ Physiol*. 2006;291:H985–1002, <http://dx.doi.org/10.1152/ajpheart.00292.2006>.
- Arrebola-Moreno AL, Laclaustra M, Kaski JC. Noninvasive assessment of endothelial function in clinical practice [Article in English, Spanish]. *Rev Esp Cardiol (Engl Ed)*. 2012;65:80–90, <http://dx.doi.org/10.1016/j.recresp.2011.09.012>.
- Cecelja M, Chowienzyk P. Role of arterial stiffness in cardiovascular disease. *JRSM Cardiovasc Dis*. 2012;1, <http://dx.doi.org/10.1258/cvd.2012.012016>.
- Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, et al. CAFE Investigators; Anglo-Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee and Writing Committee. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. *Circulation*. 2006;113:1213–25, <http://dx.doi.org/10.1161/CIRCULATIONAHA.105.595496>.
- Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. *Eur Heart J*. 2018;39:3021–104, <http://dx.doi.org/10.1093/eurheartj/ehy339>. Erratum in: *Eur Heart J*. 2019;40:475.
- Benetos A, Thomas F, Joly L, Blacher J, Pannier B, Labat C, et al. Pulse pressure amplification: a mechanical biomarker of cardiovascular risk. *J Am Coll Cardiol*. 2010;55:1032–7, <http://dx.doi.org/10.1016/j.jacc.2009.09.061>.
- Vlachopoulos C, Aznaouridis K, O'Rourke MF, Safar ME, Baou K, Stefanadis C. Prediction of cardiovascular events and

- all-cause mortality with central haemodynamics: a systematic review and meta-analysis. *Eur Heart J*. 2010;31:1865–71, <http://dx.doi.org/10.1093/eurheartj/ehq024>.
10. Kollias A, Lagou S, Zeniodi ME, Boubouchairopoulou N, Stergiou GS. Association of central versus brachial blood pressure with target-organ damage: systematic review and meta-analysis. *Hypertension*. 2016;67:183–90, <http://dx.doi.org/10.1161/HYPERTENSIONAHA.115.06066>.
 11. Roman MJ, Devereux RB, Kizer JR, Lee ET, Galloway JM, Ali T, et al. Central pressure more strongly relates to vascular disease and outcome than does brachial pressure: the strong heart study. *Hypertension*. 2007;50:197–203, <http://dx.doi.org/10.1161/HYPERTENSIONAHA.107.089078>.
 12. Weber T, Auer J, O'Rourke MF, Kvas E, Lassnig E, Berent R, et al. Arterial stiffness, wave reflections, and the risk of coronary artery disease. *Circulation*. 2004;109:184–9, <http://dx.doi.org/10.1161/01.CIR.0000105767.94169.E3>.
 13. McEnery CM, Yasmin, Hall IR, Qasem A, Wilkinson IB, Cockcroft JR. ACCT Investigators. Normal vascular aging: differential effects on wave reflection and aortic pulse wave velocity: the Anglo-Cardiff Collaborative Trial (ACCT). *J Am Coll Cardiol*. 2005;46:1753–60, <http://dx.doi.org/10.1016/j.jacc.2005.07.037>.
 14. Jerrard-Dunne P, Mahmud A, Feely J. Ambulatory arterial stiffness index, pulse wave velocity and augmentation index—interchangeable or mutually exclusive measures? *J Hypertens*. 2008;26:529–34, <http://dx.doi.org/10.1097/HJH.0b013e3282f35265>.
 15. Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D, et al. European Network for Non-invasive Investigation of Large Arteries. Expert consensus document on arterial stiffness: methodological issues and clinical applications. *Eur Heart J*. 2006;27:2588–605, <http://dx.doi.org/10.1093/eurheartj/ehl254>.
 16. Reference Values for Arterial Stiffness' Collaboration. Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: 'establishing normal and reference values'. *Eur Heart J*. 2010;31:2338–50, <http://dx.doi.org/10.1093/eurheartj/ehq165>.
 17. Herbert A, Cruickshank JK, Laurent S, Boutouyrie P. Reference Values for Arterial Measurements Collaboration. Establishing reference values for central blood pressure and its amplification in a general healthy population and according to cardiovascular risk factors. *Eur Heart J*. 2014;35:3122–33, <http://dx.doi.org/10.1093/eurheartj/ehu293>.
 18. Wojciechowska W, Staessen JA, Nawrot T, Cwynar M, Seidlerová J, Stolarz K, et al. European Project on Genes in Hypertension (EPOGH) Investigators. Reference values in white Europeans for the arterial pulse wave recorded by means of the SphygmoCor device. *Hypertens Res*. 2006;29:475–83, <http://dx.doi.org/10.1291/hypres.29.475>.
 19. Janner JH, Godtfredsen NS, Ladelund S, Vestbo J, Prescott E. Aortic augmentation index: reference values in a large unselected population by means of the SphygmoCor device. *Am J Hypertens*. 2010;23:180–5, <http://dx.doi.org/10.1038/ajh.2009.234>.
 20. Gómez-Sánchez M, Patino-Alonso MC, Gómez-Sánchez L, Recio-Rodríguez JI, Rodríguez-Sánchez E, Maderuelo-Fernández JA, et al. EVA Group. Reference values of arterial stiffness parameters and their association with cardiovascular risk factors in the Spanish population. The EVA study [Article in English, Spanish]. *Rev Esp Cardiol (Engl Ed)*. 2020;73:43–52, <http://dx.doi.org/10.1016/j.rec.2019.04.016>.
 21. Gestational hypertension and preeclampsia: ACOG practice bulletin, number 222. *Obstet Gynecol*. 2020;135:e237–60, <http://dx.doi.org/10.1097/AOG.0000000000003891>.
 22. Tranquilli AL, Brown MA, Zeeman GG, Dekker G, Sibai BM. The definition of severe and early-onset preeclampsia. Statements from the International Society for the Study of Hypertension in Pregnancy (ISSHP). *Pregnancy Hypertens*. 2013;3:44–7, <http://dx.doi.org/10.1016/j.pregphy.2012.11.001>.
 23. Bos WJ, Verrij E, Vincent HH, Westerhof BE, Parati G, van Montfrans GA. How to assess mean blood pressure properly at the brachial artery level. *J Hypertens*. 2007;25:751–5, <http://dx.doi.org/10.1097/HJH.0b013e32803fb621>.
 24. Avolio AP, Van Bortel LM, Boutouyrie P, Cockcroft JR, McEnery CM, Protogerou AD, et al. Role of pulse pressure amplification in arterial hypertension: experts' opinion and review of the data. *Hypertension*. 2009;54:375–83, <http://dx.doi.org/10.1161/HYPERTENSIONAHA.109.134379>. Erratum in: *Hypertension*. 2011;58:e30.
 25. Chambers JC, Fusi L, Malik IS, Haskard DO, De Swiet M, Kooner JS. Association of maternal endothelial dysfunction with preeclampsia. *JAMA*. 2001;285:1607–12, <http://dx.doi.org/10.1001/jama.285.12.1607>.
 26. Yinon Y, Kingdom JC, Odutayo A, Moineddin R, Drewlo S, Lai V, et al. Vascular dysfunction in women with a history of preeclampsia and intrauterine growth restriction: insights into future vascular risk. *Circulation*. 2010;122:1846–53, <http://dx.doi.org/10.1161/CIRCULATIONAHA.110.948455>.
 27. Rönneck M, Lampinen K, Groop PH, Kaaja R. Pulse wave reflection in currently and previously preeclamptic women. *Hypertens Pregnancy*. 2005;24:171–80, <http://dx.doi.org/10.1081/PRG-200059871>.
 28. Kirillos S, Skilton M, Patel S, Arnott C. A systematic review of vascular structure and function in pre-eclampsia: non-invasive assessment and mechanistic links. *Front Cardiovasc Med*. 2019;6:166, <http://dx.doi.org/10.3389/fcvm.2019.00166>.
 29. Germain AM, Romanik MC, Guerra I, Solari S, Reyes MS, Johnson RJ, et al. Endothelial dysfunction: a link among preeclampsia, recurrent pregnancy loss, and future cardiovascular events? *Hypertension*. 2007;49:90–5, <http://dx.doi.org/10.1161/01.HYP.0000251522.18094.d4>.
 30. Paradisi G, Biaggi A, Savone R, Ianniello F, Tomei C, Caforio L, et al. Cardiovascular risk factors in healthy women with previous gestational hypertension. *J Clin Endocrinol Metab*. 2006;91:1233–8, <http://dx.doi.org/10.1210/jc.2005-1337>.
 31. Khalil A, Jauniaux E, Harrington K. Antihypertensive therapy and central hemodynamics in women with hypertensive disorders in pregnancy. *Obstet Gynecol*. 2009;113:646–54, <http://dx.doi.org/10.1097/AOG.0b013e318197c392>.
 32. Lampinen KH, Rönneck M, Kaaja RJ, Groop PH. Impaired vascular dilatation in women with a history of pre-eclampsia. *J Hypertens*. 2006;24:751–6, <http://dx.doi.org/10.1097/01.hjh.0000217859.27864.19>.
 33. Hausvater A, Giannone T, Sandoval YH, Doonan RJ, Antonopoulos CN, Matsoukis IL, et al. The association between preeclampsia and arterial stiffness. *J Hypertens*. 2012;30:17–33, <http://dx.doi.org/10.1097/HJH.0b013e32834e4b0f>.
 34. Ostlund E, Al-Nashi M, Hamad RR, Larsson A, Eriksson M, Bremme K, et al. Normalized endothelial function but sustained cardiovascular risk profile 11 years following a pregnancy complicated by preeclampsia. *Hypertens Res*. 2013;36:1081–7, <http://dx.doi.org/10.1038/hr.2013.81>.
 35. Christensen M, Kronborg CS, Eldrup N, Rossen NB, Knudsen UB. Preeclampsia and cardiovascular disease risk assessment — do arterial stiffness and atherosclerosis uncover increased risk ten years after delivery? *Pregn Hypertens*. 2016;6:110–4, <http://dx.doi.org/10.1016/j.pregphy.2016.04.001>.
 36. Avni B, Frenkel G, Shahar L, Golik A, Sherman D, Dishy V. Aortic stiffness in normal and hypertensive pregnancy. *Blood Press*. 2010;19:11–5, <http://dx.doi.org/10.3109/08037050903464535>.

37. Wilkinson IB, Prasad K, Hall IR, Thomas A, MacCallum H, Webb DJ, et al. Increased central pulse pressure and augmentation index in subjects with hypercholesterolemia. *J Am Coll Cardiol.* 2002;39:1005–11, [http://dx.doi.org/10.1016/s0735-1097\(02\)01723-0](http://dx.doi.org/10.1016/s0735-1097(02)01723-0).
38. Jatoi NA, Jerrard-Dunne P, Feely J, Mahmud A. Impact of smoking and smoking cessation on arterial stiffness and aortic wave reflection in hypertension. *Hypertension.* 2007;49:981–5, <http://dx.doi.org/10.1161/HYPERTENSIONAHA.107.087338>. Erratum in: *Hypertension.* 2007 Jul;50:e11.
39. Wildman RP, Farhat GN, Patel AS, Mackey RH, Brockwell S, Thompson T, et al. Weight change is associated with change in arterial stiffness among healthy young adults. *Hypertension.* 2005;45:187–92, <http://dx.doi.org/10.1161/01.HYP.0000152200.10578.5d>.
40. Lantelme P, Mestre C, Lievre M, Gressard A, Milon H. Heart rate: an important confounder of pulse wave velocity assessment. *Hypertension.* 2002;39:1083–7, <http://dx.doi.org/10.1161/01.hyp.0000019132.41066.95>.
41. Lacy PS, O'Brien DG, Stanley AG, Dewar MM, Swales PP, Williams B. Increased pulse wave velocity is not associated with elevated augmentation index in patients with diabetes. *J Hypertens.* 2004;22:1937–44, <http://dx.doi.org/10.1097/00004872-200410000-00016>.
42. Wilkinson IB, MacCallum H, Flint L, Cockcroft JR, Newby DE, Webb DJ. The influence of heart rate on augmentation index and central arterial pressure in humans. *J Physiol.* 2000;525:263–70, <http://dx.doi.org/10.1111/j.1469-7793.2000.t01-1-00263.x>.
43. Franz MB, Burgmann M, Neubauer A, Zeisler H, Sanani R, Gottsauner-Wolf M, Schiessl B, et al. Augmentation index and pulse wave velocity in normotensive and pre-eclamptic pregnancies. *Acta Obstet Gynecol Scand.* 2013;92:960–6, <http://dx.doi.org/10.1111/aogs.12145>.
44. Laurent P, Albaladejo P, Blacher J, Rudnichi A, Smulyan H, Safar ME. Heart rate and pulse pressure amplification in hypertensive subjects. *Am J Hypertens.* 2003;16:363–70, [http://dx.doi.org/10.1016/s0895-7061\(03\)00063-3](http://dx.doi.org/10.1016/s0895-7061(03)00063-3).
45. Protogerou AD, Blacher J, Mavrikakis M, Lekakis J, Safar ME. Increased pulse pressure amplification in treated hypertensive subjects with metabolic syndrome. *Am J Hypertens.* 2007;20:127–33, <http://dx.doi.org/10.1016/j.amjhyper.2006.06.014>.
46. McEniery CM, Yasmin, McDonnell B, Munnelly M, Wallace SM, Rowe CV, et al. Anglo-Cardiff Collaborative Trial Investigators. Central pressure: variability and impact of cardiovascular risk factors: the Anglo-Cardiff Collaborative Trial II. *Hypertension.* 2008;51:1476–82, <http://dx.doi.org/10.1161/HYPERTENSIONAHA.107.105445>.
47. Belmar Vega L, Fernández Fresnedo G, Irure Ventura J, Orallo Toural V, Heras Vicario M, Ruiz San Millán JC, et al. Non-criteria antiphospholipid antibodies: risk factors for endothelial dysfunction in women with pre-eclampsia. *Life.* 2020;10:241, <http://dx.doi.org/10.3390/life10100241>.
48. Jankowski P, Kawecka-Jaszcz K, Czarnecka D, Brzozowska-Kiszka M, Styczkiewicz K, Loster M, et al. Aortic Blood Pressure and Survival Study Group. Pulsatile but not steady component of blood pressure predicts cardiovascular events in coronary patients. *Hypertension.* 2008;51:848–55, <http://dx.doi.org/10.1161/HYPERTENSIONAHA.107.101725>.
49. Voicehovska JG, Bormane E, Grigane A, Moisejevs G, Moreino E, Trumpika D, et al. Association of arterial stiffness with chronic kidney disease progression and mortality. *Heart Lung Circ.* 2021;30:1694–701, <http://dx.doi.org/10.1016/j.hlc.2021.08.011>.